Theratechnologies Inc.
2310 Alfred-Nobel Boulevard
Saint-Laurent
Quebec
H4S 2A4
Canada
Tel: 514-336-7800
Fax: 514-336-7242
Website: http://www.theratech.com/
Email: webinfo@theratech.com.
326 articles about Theratechnologies Inc.
-
Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update
10/13/2022
Theratechnologies Inc. today reported business highlights and financial results for the third quarter of fiscal year 2022, ended August 31, 2022. All figures are in U.S. dollars unless otherwise stated.
-
Theratechnologies Presents Data Demonstrating High Expression of Sortilin (SORT1) in Multiple Tumor Types at 34th EORTC-NCI-AACR Symposium
10/12/2022
Theratechnologies Inc. today announced that the Company will present data from tissue microarrays showing high expression of SORT1, the target for Theratechnologies’ oncology platform, in several cancer types.
-
Theratechnologies’ Trogarzo® Approved by FDA for 30-Second Intravenous (IV) Push, Simplifying HIV Treatment for Heavily Treatment-Experienced Population
10/3/2022
Theratechnologies Inc. announced that the United States Food and Drug Administration approved Trogarzo® for administration by intravenous push, a method by which the undiluted medication is “pushed” by syringe for faster administration into the body’s circulation.
-
Theratechnologies’ Trogarzo for HIV, Alnylam’s Lumasiran for advanced primary hyperoxaluria, scPharmaceuticals' Furoscix for heart failure and more. Here's a look at the FDA's October calendar.
-
Theratechnologies to Announce Third Quarter 2022 Financial Results and Provide Business Update
9/26/2022
Theratechnologies Inc. today announced that it will report financial results for its third quarter of fiscal 2022 ended August 31, on Thursday, October 13, 2022.
-
Theratechnologies to Present at the Cantor Oncology, Hematology & HemeOnc Conference
9/19/2022
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), today announced that Paul Levesque, President and Chief Executive Officer, will participate on the “Novel Targets in Oncology: Risk vs. Reward” panel, at the Cantor Oncology, Hematology & HemeOnc Conference to be held at the New York Palace Hotel, on Wednesday, September 28, 2022, at 9:00 a.m. ET, in New York City.
-
Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth
9/12/2022
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) today announced the publication of a preclinical study demonstrating the in vitro and in vivo efficacy of TH1902, an investigational sortilin (SORT1)-targeted peptide-drug conjugate, in inhibiting ovarian cancer and triple-negative breast cancer (TNBC) stem-like cells’ (CSCs) tumor growth.
-
Theratechnologies to Present at the Canaccord Genuity 42nd Annual Growth Conference
8/2/2022
Theratechnologies Inc. will participate in a fireside chat at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, August 10, 2022 at 1:00 p.m. ET.
-
Theratechnologies Trogarzo® Data at AIDS 2022 Shows Potential for Improved Treatment Regimens
7/28/2022
Theratechnologies Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced data from two poster presentations at the 24th International AIDS Conference, being held from July 29 to August 2 in Montreal, Canada and virtually.
-
Theratechnologies Announces Closing of Funding of $40 Million Under the Terms of its Credit Agreement
7/27/2022
Theratechnologies Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced that it has received funding of $40 million under the terms of its credit agreement with affiliated funds of Marathon Asset Management.
-
Theratechnologies Reports Second Quarter and First Half Fiscal 2022 Financial Results and Provides Business Update
7/14/2022
Theratechnologies Inc. today reported business highlights and financial results for the second quarter and first half of fiscal year 2022 ended May 31, 2022. All figures are in U.S. dollars unless otherwise stated.
-
Theratechnologies Provides Update on the Dose Escalation Portion of Fast Track Designated TH1902 First-in-Human Study in Advanced Resistant Malignancies
7/14/2022
Theratechnologies Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies, provided an update on the dose escalation portion of the TH1902 Phase 1 clinical safety study.
-
Theratechnologies Announces Binding Commitment for a Non-Dilutive Term Loan of up to $100 million from Marathon Asset Management
7/13/2022
Financing Will Significantly Strengthen the Balance Sheet and Extend Cash Runway.
-
CQDM, the Quebec Breast Cancer Foundation and Theratechnologies fund close to $2 million for research project to validate the anti-metastatic potential of TH1902 at the Université du Québec à Montréal
7/12/2022
CQDM, the Quebec Breast Cancer Foundation and Theratechnologies announced close to CAN $2 million of funding for a collaborative research project that aims to demonstrate the efficacy and safety of a potential innovative treatment for patients affected by metastatic cancer.
-
Theratechnologies to Announce Second Quarter 2022 Financial Results and Provide Business Update
7/7/2022
Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results for its second quarter of fiscal 2022 ended May 31 on Thursday, July 14, 2022.
-
Theratechnologies Announces New Head of Investor Relations
5/31/2022
Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Elif McDonald has joined the team as Senior Director, Investor Relations.
-
Achilles dosed the first patient in a Phase I/IIa advanced NSCLC trial, Logic Bio's pediatric methylmalonic acidemia study is back up and running and another look at Roche's TIGIT flop.
-
Theratechnologies Initiates Basket Portion of TH1902 First-in-Human Study in Advanced Resistant Malignancies
5/10/2022
Theratechnologies Inc. a biopharmaceutical company focused on the development and commercialization of innovative therapies, today initiated enrollment of patients in the basket portion of the first-in-human study of TH1902, Theratechnologies’ investigational lead peptide drug conjugate (PDC) for the treatment of sortilin-expressing cancers.
-
Theratechnologies Reports Financial Results for First Quarter Fiscal 2022 and Provides Business Update
4/13/2022
Theratechnologies Inc. today reported business highlights and financial results for the first quarter of fiscal year 2022 ended February 28, 2022 (Q1 2022).
-
Theratechnologies to Announce Financial Results for Its First Quarter 2022
3/31/2022
Theratechnologies Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced that it will report financial results for its first quarter of fiscal 2022 ended February 28, 2022 on Wednesday, April 13, 2022.